Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
Status:
Completed
Trial end date:
2018-10-24
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and efficacy of
sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C
infection who have failed to eradicate hepatitis C despite previous combination directly
acting antiviral therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore